IgLON Family Member 5 (IgLON5) Antibody, IgG by CBA-IFA With Reflex to Titer, Serum
Aids in the diagnosis of neurodegenerative disease and limbic encephalitis. May be used to monitor treatment response in individuals who are antibody positive. The presence of IgLON5 antibodies may be associated with sleep disorders, bulbar symptoms, gait problems, cognitive dysfunction, movement disorders, or dysautonomia. IgLON5 autoimmune neurologic/neurodegenerative disorders may be paraneoplastic, but tumor type is variable.
New York DOH Approval Status
Serum separator tube.
Separate serum from cells within 2 hours of collection. Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.2 mL)
CSF or plasma. Contaminated, grossly hemolyzed, icteric, or lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month (Three freeze/thaw cycles are acceptable)
Semiquantitative Cell-Based Indirect Fluorescent Antibody
Less than 1:10
IgLON Family Member 5 (IgLON5) antibody is found in a subset of patients with autoimmune encephalitis or other autoimmune neurologic/neurodegenerative disorders and may occur with or without associated tumor. A negative test result does not rule out a diagnosis of an autoimmune neurologic disorder. Interpretation of any antineural antibody test requires clinical correlation.
This indirect fluorescent antibody assay utilizes IgLON5 transfected cell lines for detection and semiquantification of IgLON5 IgG antibody.
Laboratory Developed Test (LDT)
If IgLON5 antibody IgG is positive, then IgLON5 antibody IgG titer will be added. Additional charges apply.
86255; if reflexed, add 86256
|Component Test Code*||Component Chart Name||LOINC|
|3006019||IgLON5 Ab IgG CBA-IFA Screen, Serum||96478-3|
- autoimmune encephalitis
- IgLON 5
- Limbic encephalitis
- movement disorder
- neurodegenerative disease
- sleep disorder